Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04666649 · ClinicalTrials.gov registry record · Phase 1
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04666649 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 27 participants.
The verdict
NCT04666649, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
Evaluate the safety and tolerability of pegcrisantaspase in combination with venetoclax (Ven-PegC) and estimate the maximum tolerated doses and/or biologically active doses of Ven-PegC in patients with relapsed or refractory acute myeloid leukemia (R/R AML)
Interventions
- DRUG Venetoclax and pegcrisantaspase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2025-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04666649
The ClinicalTrials.gov registry entry for NCT04666649 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Venetoclax and pegcrisantaspase is the first listed.
NCT04666649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04666649 about?
NCT04666649 is a clinical study titled "Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)". Evaluate the safety and tolerability of pegcrisantaspase in combination with venetoclax (Ven-PegC) and estimate the maximum tolerated doses and/or biologically active doses of Ven-PegC in patients with relapsed or refractory acute myeloid leukemia (R/R AML)
What is the current status of trial NCT04666649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2021-03-10. Estimated completion is 2025-05-23.
What interventions are being tested in trial NCT04666649?
The interventions under investigation include: Venetoclax and pegcrisantaspase (DRUG).
Who is sponsoring clinical trial NCT04666649?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.